Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Watson Buying Arrow In Generics Deal

by Michael McCoy
June 22, 2009 | A version of this story appeared in Volume 87, Issue 25

Watson Pharmaceuticals has agreed to acquire privately held Arrow Group for $1.75 billion in cash and stock. The resulting generic drug company will have more than $3 billion in annual sales. According to Watson, Arrow's sales last year were $647 million and included more than 100 molecules in 20 countries. Arrow has U.S. rights to launch the authorized generic version of Lipitor in November 2011. It also owns 36% of Eden Biodesign, a biopharmaceutical firm that Watson says will provide a foundation for future generic biologics.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.